Rebounding Teva is 'too cheap to ignore,' upbeat analysts say | Fierce Pharma
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters
Teva cut to Sell at UBS citing uncertainty over leadership transition (NYSE: TEVA) | Seeking Alpha
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Summer of Teva: The Mom Comfort Sandal
Storbank blåstempler Kåre Schultz' plan for Teva: Aktien er »for billig til at ignorere«
UBS raises Teva price target - Globes
Teva hires ex-Novartis executive to succeed CEO Schultz | Reuters
AMD, Nike, Zillow among UBS stock picks with the 'highest conviction' for 2023 - MarketWatch
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action - ADVFN
UBS cuts estimate of Teva's opioid liability - Globes
As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites | Ctech
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva started at neutral at UBS on pricing and legal concerns (NYSE:TEVA) | Seeking Alpha
Jennifer Bryan - Head of Commercial Training & Development - Teva Pharmaceuticals | LinkedIn
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
Teva says vaccine makers have not taken its offer to help produce jabs | Financial Times
Teva Pharmaceuticals Archives - Drug Discovery and Development
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
Teva Has Potential For 6% CAGR Ahead, UBS Says In Upgrade
